BEAMBeam Therapeutics Inc.

$3B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6,000+0.0% YoY

Gross Profit

-$190M-3168333.3% margin

Operating Income

-$200M-3339550.0% margin

Net Income

-$202M-3359333.3% margin

EPS (Diluted)

$-3.35

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$50M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$693M

Total Liabilities

$271M

Stockholders' Equity

$422M

Cash & Equivalents

$97M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6,000	$6,000	+0.0%
Gross Profit	-$190M	-$22M	-782.4%
Operating Income	-$200M	-$28M	-606.7%
Net Income	-$202M	-$30M	-561.8%

BEAM Q1 2021 Earnings — Beam Therapeutics Inc. Revenue & Financial Results | Market Cap Arena